Vaxxinity, Inc. (VAXX) Reports In-Line Q4 EPS

Go back to Vaxxinity, Inc. (VAXX) Reports In-Line Q4 EPS

Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates

March 27, 2023 7:50 AM EDT

CAPE CANAVERAL, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2022.

We are grateful for and proud of our accomplishments in our first full year as a public company, and remain on track to continue to hit our... More